Dupixent Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Dupixent Growth

1. Market Share Gains and New Patient Starts

• Dupixent continues to achieve strong market share growth across multiple immunology and inflammatory conditions.
• A steady rise in new patient starts is fueling robust prescription demand, particularly in dermatology and respiratory indications.
• Sanofi and Regeneron's expansive commercial strategy, physician engagement programs, and patient support services are further boosting adoption.

2. Expansion Across Key Indications

• Atopic Dermatitis (AD): Dupixent remains the leading therapy for moderate-to-severe atopic dermatitis globally, with significant penetration in both adult and pediatric populations.
• Asthma: Widely prescribed as an add-on therapy for moderate-to-severe asthma, showing strong uptake due to its targeted mechanism of action and proven efficacy in reducing exacerbations.
• Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP): Established as a go-to therapy in this underserved segment, with growing patient volumes.
• Eosinophilic Esophagitis (EoE): Recently approved use is expanding Dupixent's presence in gastroenterology.
• Chronic Spontaneous Urticaria (CSU): Ongoing development in this space positions Dupixent to further strengthen its dermatology portfolio.
• Pipeline developments also point to potential future applications in COPD and other allergic/inflammatory conditions, expanding Dupixent's reach.

3. Geographic Expansion

• Dupixent is now available in over 60 countries, with continued rollout in both developed and emerging markets.
• Asia-Pacific markets are delivering strong double-digit growth, supported by rising diagnosis rates and better access to biologics.
• Sanofi and Regeneron are building local infrastructure and partnerships to enhance market penetration and speed of uptake.

4. New Indication Approvals

• Regulatory approvals for pediatric atopic dermatitis and pediatric asthma significantly expanded Dupixent's eligible patient base.
• Recent FDA and EMA approvals for eosinophilic esophagitis have opened a new therapeutic area with high unmet need.
• Ongoing regulatory submissions for chronic spontaneous urticaria and COPD will further diversify its indications and revenue streams.

5. Strong Respiratory and Dermatology Volume Momentum

• Dupixent is driving strong growth in dermatology (AD) and respiratory medicine (asthma, CRSwNP).
• Increasing real-world use and long-term data continue to validate its safety and efficacy across broad patient populations.
• Sustained growth in EoE prescriptions reflects its ability to address niche but high-need patient populations.

6. Competitive Differentiation and Market Trends

• As the first and only biologic targeting IL-4 and IL-13 pathways, Dupixent offers a differentiated mechanism addressing Type 2 inflammation.
• Its broad multi-indication label across dermatology, respiratory, and gastroenterology sets it apart from competitors.
• Strong efficacy, durable responses, and a favorable safety profile compared to systemic immunosuppressants reinforce physician and patient preference.
• Broader market trends toward biologics, precision immunology, and patient-centric care models support Dupixent's leadership position.
• Growing reliance on Real-World Evidence (RWE) continues to strengthen payer coverage and market access.

Dupixent Recent Developments

• In June 2025, Just over three-quarters, 76%, of patients receiving Sanofi and Regeneron's Dupixent (dupilumab) achieved at least a 75% improvement in overall disease severity (EASI-75), the primary endpoint of the DISCOVER Phase IV study.
• In April 2025, the US Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.
• In March 2025, Regeneron Pharmaceuticals and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy.

"Dupixent Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Dupixent for approved indications like Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Chronic urticaria; Eosinophilic oesophagitis; Prurigo nodularis; Rhinosinusitis; as well as potential indications like Ulcerative colitis, and Aspergillosis in the 7MM. A detailed picture of Dupixent's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Dupixent for approved and potential indications. The Dupixent market report provides insights about Dupixent's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Dupixent performance, future market assessments inclusive of the Dupixent market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Dupixent sales forecasts, along with factors driving its market.

Dupixent Drug Summary

Dupixent (dupilumab) is an injection administered under the skin (subcutaneous injection) at different injection sites. In adults with BP, Dupixent 300 mg is administered every other week after an initial loading dose, and in combination with a tapering course of oral corticosteroids. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare professional.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, and BP in different age populations. More than one million patients are being treated with Dupixent globally. The report provides Dupixent's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Dupixent is in the Phase II stage of clinical development for the treatment of patients with Ulcerative colitis (NCT05731128) and Aspergillosis (NCT04442269).

Scope of the Dupixent Market Report

The report provides insights into:

• A comprehensive product overview including the Dupixent MoA, description, dosage and administration, research and development activities in approved indications like Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Chronic urticaria; Eosinophilic oesophagitis; Prurigo nodularis; Rhinosinusitis; as well as potential indications like Ulcerative colitis, and Aspergillosis.
• Elaborated details on Dupixent regulatory milestones and other development activities have been provided in Dupixent market report.
• The report also highlights Dupixent's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Dupixent market report also covers the patents information, generic entry and impact on cost cut.
• The Dupixent market report contains current and forecasted Dupixent sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Dupixent market report also features the SWOT analysis with analyst views for Dupixent in approved and potential indications.

Methodology:

The Dupixent market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Dupixent Analytical Perspective by DelveInsight

• In-depth Dupixent Market Assessment

This Dupixent sales market forecast report provides a detailed market assessment of Dupixent for approved indications like Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Chronic urticaria; Eosinophilic oesophagitis; Prurigo nodularis; Rhinosinusitis; as well as potential indications like Ulcerative colitis, and Aspergillosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Dupixent sales data uptil 2034.

• Dupixent Clinical Assessment

The Dupixent market report provides the clinical trials information of Dupixent for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Dupixent Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Dupixent Market Potential & Revenue Forecast

• Projected market size for the Dupixent and its key indications
• Estimated Dupixent sales potential (Dupixent peak sales forecasts)
• Dupixent Pricing strategies and reimbursement landscape

Dupixent Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Dupixent Market positioning compared to existing treatments
• Dupixent Strengths & weaknesses relative to competitors

Dupixent Regulatory & Commercial Milestones

• Dupixent Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Dupixent Clinical Differentiation

• Dupixent Efficacy & safety advantages over existing drugs
• Dupixent Unique selling points

Dupixent Market Report Highlights

• In the coming years, the Dupixent market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Dupixent companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Dupixent's dominance.
• Other emerging products for Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Chronic urticaria; Eosinophilic oesophagitis; Prurigo nodularis; Rhinosinusitis; as well as potential indications like Ulcerative colitis, and Aspergillosis are expected to give tough market competition to Dupixent and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Dupixent in approved and potential indications.
• Analyse Dupixent cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Dupixent sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Dupixent in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Dupixent? How strong is Dupixent's clinical and commercial performance?
• What is Dupixent's clinical trial status in each individual indications such as Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Chronic urticaria; Eosinophilic oesophagitis; Prurigo nodularis; Rhinosinusitis; as well as potential indications like Ulcerative colitis, and Aspergillosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Dupixent Manufacturers?
• What are the key designations that have been granted to Dupixent for approved and potential indications? How are they going to impact Dupixent's penetration in various geographies?
• What is the current and forecasted Dupixent market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Dupixent in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Dupixent for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Dupixent? What is the duration of therapy and what are the geographical variations in cost per patient?